February 27, 2017 / 6:01 AM / 5 months ago

Sanofi and Lonza to build biologics facility in Switzerland

1 Min Read

PARIS, Feb 27 (Reuters) - French drugmaker Sanofi and Switzerland's Lonza will invest 270 million euros ($285 million) to build a large-scale biologics facility that will produce monoclonal antibodies by 2020, the two companies said on Monday.

Pending regulatory approvals, the facility, which will be established through a 50-50 joint venture, will be located in Visp, Switzerland, Sanofi and Lonza said in a joint statement.

By contrast to most drugs that are chemically synthesized, many biologics are produced using living cells. They are seen as a promising answer in areas such as cardiovascular, neurology or cancer treatments.

$1 = 0.9471 euros Reporting by Matthias Blamont; editing by Jason Neely

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below